US-based biopharmaceutical company Tobira Therapeutics has raised $31m in its series B round led by Denmark-based medical foundation Novo.
Venture capital firm Domain Associates, which incubated the company in 2006 to develop treatments for HIV disease, also invested in the B round consortium alongside peers Frazier Healthcare Ventures, Montreux Equity Partners and Canaan Partners.